Can a cancer drug shrink tumors in men with a key gene loss?

NCT ID NCT06029998

Ongoing Disease control Sponsor: University of Utah Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times

Summary

This phase 2 trial tests the drug bortezomib in 22 men with metastatic castration-resistant prostate cancer that has a specific genetic change (PTEN deletion). The main goal is to see if bortezomib can lower PSA levels by at least 30%. Participants receive bortezomib injections for up to 8 cycles (about 21 days each).

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bortezomib
What this could lead to: If it works, this could point toward a new treatment option for men with this specific type of advanced prostate cancer.
What could go wrong: This is a small, early-phase trial with only 22 participants, so results may not apply broadly. Bortezomib can cause side effects like nerve damage and low blood counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Contacts and locations

Locations

Huntsman Cancer Institute/University of Utah

Salt Lake City, Utah, 84112, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.